The objective of this study was to determine whether differences in tissue accumulation observed upon multiple dosing of aminoglycosides in hospitalized patients could be identified in appropriate single-dose studies in normal volunteers. Ten volunteers received single intravenous doses of 1.0 mg of gentamicin and tobramycin per kg of body weight in randomized crossover fashion. Multiple serum and urine samples were collected during the next 30 days. Serum aminoglycoside concentrations and urinary excretion rates were fitted to a twocompartment pharmacokinetic model, and parameters were derived. Tobramycin exhibited a higher clearance (P < 0.08) and a lower volume of distribution at steady state (P < 0.1), neither of which was significant. Tobramycin also showed a significantly lower predicted amount of drug in the body at steady state (P < 0.05). These differences are consistent with observations made in patients receiving multiple doses. Single-dose studies appear to be capable of discriminating pharmacokinetic characteristics relevant to the comparative nephrotoxic potential of these two aminoglycosides.
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Recent studies have established a significant difference between gentamicin and tobramycin in the incidence of nephrotoxicity (13, 16) . In previous studies, we have proposed a relationship between tissue accumulation, as described by an open two-compartment model, and subsequent nephrotoxicity for both gentamicin and tobramycin (8, 11, 12) . These studies required hundreds of treated patients owing to the large amount of intersubject variance in a population of critical-care patients. In reviewing the details of these investigations, we noted that the pharmacokinetic parameters of patients who received single doses were predictive of the pharmacokinetic parameters observed in multipledose therapy. These pharmacokinetic parameters may identify the risk of toxicity in patients before overt renal damage occurs (14) . In Serum and urine samples were assayed for aminoglycoside concentration by radioimmunoassay (RIANEN, New England Nuclear Corp.). The coefficient of variation for this assay ranged from 5 to 10o over the concentration range studied. Urinary P2Mi-croglobulin was analyzed by radioimmunoassay (Pharmacia Fine Chemicals), and alanine aminopeptidase was assayed by an enzymatic method (15) . Cast counts (9) were performed within 24 h of urine sample collection.
By means of the computer program NONLIN, serum aminoglycoside concentrations and urinary excretion rates were fitted independently to a twocompartment open model (2) . Independent fitting was necessary for two reasons. First, renal clearance was nonlinear early in the terminal elimination phase (10 Table 1 . Single-dose gentamicin data were in excellent agreement with the data for gentamicin determined after multiple dosing, even though the patient exhibited nephrotoxicity during multiple dosing. Most important, the predicted XbSS for the single dose was almost identical to the Xbss measured from urine excretion after multiple dosing. Treatment of the patient with both aminoglycosides allows a comparison between single doses of gentamicin and tobramycin. This comparison revealed less extensive tissue accumulation potential for tobramycin (Table 1) .
Crossover study. In the 10 volunteers, no significant changes from base-line values were observed in audiometry, cast excretion, alanine aminopeptidase excretion, or creatinine clearance. All hematology and serum chemistry tests also remained within the normal ranges throughout the studies. No discomfort or side effects were reported. Urine mass balance was complete within 30 days, at which time 99 ± 6% of the administered dose had been recovered in the urine. Only 70 to 90% of the administered dose was recovered in the first 24 h. These 24-h recovery values agree with those obtained in previous 24-h single-dose studies (5) and illustrate why extended urine collections are needed to achieve total recovery of the administered dose. Two-compartment pharmacokinetic parameters for tobramycin and gentamicin are given in Table 2 . No significant differences between tobramycin and gentamicin were detected in the volume of the central compartment and the terminal half-life. Tobramycin was cleared from the body more rapidly than gentamicin and had a lower volume of distribution at steady state in 8 of the 10 volunteers (Table 2 ), but these differences were not significant. Total clearance values were plotted against creatinine clearances for the individual subjects (Fig. 1) . Both aminoglycosides exhibited clearances consistently lower than the corresponding creatinine clearances, as shown by the identity line drawn for reference.
Values for XbsS differed significantly between the two agents ( Table 2 ). Of the 10 volunteers, 9 showed greater XbsS for gentamicin than for tobramycin (P < 0.03). An X-Y plot of crossover Xbss values demonstrated significantly greater gentamicin tissue uptake within each subject (Fig. 2) .
Simulations were performed based on the mean single-dose data for each of the aminoglycosides. The mean data (Fig. 3) indicate that a primary difference between the serum profiles of these two aminoglycosides is in the B intercept.
Tobramycin exhibited a more rapid decline to lower serum concentrations before entering the terminal phase. Figure 3 illustrates the lower intercept and smaller steady-state distribution volume of tobramycin and also explains the slightly higher tobramycin clearance noted in Table 2 . 
DISCUSSION
Although the one-compartment model has been used to describe aminoglycoside pharmacokinetics since the introduction of these drugs, there are compelling reasons why this simplistic modeling approach should be qualified. The aminoglycosides exhibit at least triexponential pharmacokinetics, and we have primarily studied the second and third phases of decline as the ANTIMICROB. AGENTS CHEMOTHER. physiologically relevant components. We have found that in patients the later two phases can be employed to estimate tissue accumulation of these compounds. Tissue accumulation is characteristic of all persons who receive these agents (12) , and the initial tissue accumulation rate is at least two to three times more rapid in patients who develop nephrotoxicity than in patients who do not (8) . Finally, aminoglycosides such as gentamicin and tobramycin have different accumulation rates, and these differences are associated with a lower nephrotoxic potential for tobramycin than for gentamicin in large studies of patients (13) . Other clinical studies of comparative nephrotoxicity verify the difference between gentamicin and tobramycin (16) but have not as yet assessed tissue accumulation as an integral part of study design.
Intersubject variance in tissue accumulation has been the principal reason why large numbers of patients have been required to establish pharmacokinetic differences between gentamicin and tobramycin. However, our case report and this small study in 10 volunteers indicate that the effects of wide intersubject variance can be overcome by using a randomized crossover design.
The basic premise underlying this study is that tissue accumulation and other two-compartment pharmacokinetic parameters are intrinsic characteristics of each individual and that they show little change from year to year. This hypothesis does not preclude aging effects on tissue, which (13, 14) . Finally, 9 of the 10 volunteers in this study uniformly accumulated gentamicin at greater rates than tobramycin, even though the order of exposure was randomized.
We believe that 2 months between exposures is adequate time to remove all possible effects of the previous aminoglycoside dosage. Certainly the turnover rate of renal proximal tubular lining cells is fast enough for 2 months between exposures to ensure that these cells are free of aminoglycosides for each dose. Furthermore, these single doses were well tolerated by the volunteers since no evidence of even minor tubular effects was noted with sensitive tests such as 32Microglobulin and alanine aminopeptidase.
Independent fitting of the serum concentrations and urinary excretion rate allowed the use of a two-compartment model, even after a single VOL. 22, 1982 on November 2, 2017 by guest http://aac.asm.org/ dose. This approach appears to be sensitive enough to detect differences in the distribution and elimination of tobramycin and gentamicin.
The pharmacokinetics of aminoglycosides determined after single doses appear to be predictive of the parameters and tissue accumulations seen on multiple dosing. Screening potential new aminoglycosides in such a system could substantially shorten the development time of safer molecules. In view of recent challenges to the relevance of animal models (1, 4, 7) , the pharmacokinetic methodology proposed here has the ultimate advantage of testing the relative nephrotoxic potential of new aminoglycosides in a model system more closely aligned to their ultimate use. Furthermore, this approach may be applied without exposing volunteers to the risk of nephrotoxic side effects, which develop only upon multiple dosing (3).
